Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical, Inc. SWAV reported first-quarter 2024 earnings per share (EPS) of $1.44, which beat the Zacks Consensus Estimate of $1.04 by 38.46%. The company reported an EPS of $1.03 in the year-ago quarter.

Revenue Details

Revenues totaled $218.8 million, indicating an uptick of 36% from the prior-year period’s level. The top line also beat the Zacks Consensus Estimate by 5.66%. The growth was primarily driven by an increase in the purchase volume of products, both in the United States and abroad.

Business Highlights

In April 2024, Johnson & Johnson and Shockwave Medical announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave Medical for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired. The transaction was approved by both companies’ boards of directors.

The closing of the transaction is expected to occur by mid-year 2024 subject to the receipt of Shockwave Medical’s shareholder approval, as well as the receipt of applicable regulatory approvals and other customary closing conditions.

Margins

Gross profit in the reported quarter was $190.6 million, up 36.1% year over year. As a percentage of revenues, the gross margin in the quarter was 87.1%, up 20 basis points year over year.

Sales and marketing expenses amounted to $74.5 million, up 37.9% from the prior-year quarter’s level. Research and development expenses totaled $44.5 million, up 64.9% on a year-over-year basis.

Operating income totaled $42.4 million, up 6.6% year over year.

Financial Position

Shockwave Medical exited the first quarter with cash, cash equivalents and investments of $1.03 billion compared with $990.6 million in the fourth quarter.

Total assets amounted to $1.64 billion compared with $1.57 billion at the end of the fourth quarter of 2023.

2024 Guidance Withdrawn

Given the proposed acquisition of Shockwave Medical by Johnson & Johnson, Shockwave Medical has withdrawn its full-year 2024 guidance, which was previously issued on Feb 15, 2024.

Wrapping Up

SWAV ended the first quarter on a positive note, wherein both earnings and revenues beat their respective Zacks Consensus Estimate. The company exhibited significant revenue growth in the same quarter. Per the acquisition agreement between Johnson & Johnson and Shockwave Medical, the latter is likely to expand JNJ’s MedTech cardiovascular portfolio in the two highest growth-oriented segments of cardiovascular intervention —coronary artery disease and peripheral artery disease.

ShockWave Medical, Inc. Price, Consensus and EPS Surprise

ShockWave Medical, Inc. Price, Consensus and EPS Surprise

ShockWave Medical, Inc. price-consensus-eps-surprise-chart | ShockWave Medical, Inc. Quote

Zacks Rank and Stocks to Consider

Currently, Shockwave Medical carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. ALGNEcolab ECL and Boston Scientific Corporation BSX.

Align Technology, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2024 adjusted EPS of $2.14, beating the Zacks Consensus Estimate by 8.1%. Revenues of $997.4 million outpaced the consensus mark by 2.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Align Technology has a long-term estimated growth rate of 6.9%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 5.9%.

Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.7%.

Ecolab’s shares have rallied 33.8% against the industry’s 9.3% decline in the past year.

Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, beating the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank #2.

Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 7.5%.

Where Will Stocks Go…

If Biden Wins? If Trump Wins?

The answers may surprise you.

Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!

Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…

1. Medical manufacturer has gained +11,000% in the last 15 years.

2. Rental company is absolutely crushing its sector.

3. Energy powerhouse plans to grow its already large dividend by 25%.

4. Aerospace and defense standout just landed a potentially $80 billion contract.

5. Giant Chipmaker is building huge plants in the U.S. 

Hurry, Download Special Report FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

Ecolab Inc. (ECL) : Free Stock Analysis Report

Align Technology, Inc. (ALGN) : Free Stock Analysis Report

ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.